AAIC 2025 Abstract
Women are less likely to be eligible for AD trials than men.
By Lieza Geertje Exalto, Siti S. Syaziyah, Xiaotian T. Fang, Show 4 more authorsWiesje M. van der Flier
Study in peoplePopulations
Abstract
Background: Fewer women participate in Alzheimer Disease (AD) trials than expected relative to their estimated representation in the global dementia population. Biotech, pharma, and patient organisations all aim for inclusive and representative trials, mainly focusing on participant engagement and recruitment.
